A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2004
12/22/2004	EP1487876A1 The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
12/22/2004	EP1487865A2 USES OF MAMMALIAN CYTOKINEi; RELATED REAGENTS
12/22/2004	EP1487856A2 Human antibodies specific to kdr and uses thereof
12/22/2004	EP1487843A2 Substituted phenylacetic acids
12/22/2004	EP1487831A1 Difurylglycolic acid tropenol esters used as anticholinesterase drugs
12/22/2004	EP1487829A1 Thiadiazolylpiperazine derivatives useful for treating or preventing pain
12/22/2004	EP1487824A1 Diamino-pyrimidines and their use as angiogenesis inhibitors
12/22/2004	EP1487805A1 Pyrimidine derivatives
12/22/2004	EP1487778A1 Substituted 4-aminocyclohexanols
12/22/2004	EP1487542A1 Use of asc-1 inhibitors to treat neurological and psychiatric disorders
12/22/2004	EP1487541A2 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
12/22/2004	EP1487539A1 Lower esophagus tissue modifier
12/22/2004	EP1487498A1 Topical composition comprising a cyclofructan, a carrier and a drug
12/22/2004	EP1487495A1 Combination comprising a cdk inhibitor and doxorubicin
12/22/2004	EP1487494A2 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
12/22/2004	EP1487492A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
12/22/2004	EP1487490A2 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
12/22/2004	EP1487489A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN avb3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
12/22/2004	EP1487486A2 Imidazoquinolineamines as adjuvants in hiv dna vaccination
12/22/2004	EP1487475A1 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states
12/22/2004	EP1487474A2 Intranasal administration of mc4-r agonists
12/22/2004	EP1487472A2 Stabilization of hypoxia inducible factor (hif) alpha
12/22/2004	EP1487459A1 Peptide analogues and uses thereof
12/22/2004	EP1487457A1 Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
12/22/2004	EP1487449A1 Tyrosyl derivatives and their use as p2x7 receptor modulators
12/22/2004	EP1487447A1 Use of proton pump inhibitors for the treatment of airway disorders
12/22/2004	EP1487439A1 Solubilization of weak bases
12/22/2004	EP1487436A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers
12/22/2004	EP1487435A1 Azetidine derivatives as ccr-3 receptor antagonists
12/22/2004	EP1487434A2 Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
12/22/2004	EP1487433A1 Anti-cancer combinations of dmxaa and a nsaid
12/22/2004	EP1487432A2 Suramin and derivatives thereof as topical microbicide and contraceptive
12/22/2004	EP1487431A1 Preventing and/or treating cardiovascular disease and/or associated heart failure
12/22/2004	EP1487430A1 Methods for treating diseases related to intraocular pressure
12/22/2004	EP1487424A2 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases
12/22/2004	EP1487423A1 Novel formulation
12/22/2004	EP1487414A2 Antibiotic composition
12/22/2004	EP1487413A1 An inhalation system for prevention and treatment of intracellular infections
12/22/2004	EP1487412A1 Chemosensitizing with liposomes containing oligonucleotides
12/22/2004	EP1487411A2 Inhalable sustained therapeutic formulations
12/22/2004	EP1487404A1 Use of compatible solutes for inhibiting the release of ceramides
12/22/2004	EP1333719A4 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
12/22/2004	EP1121363B1 6-SUBSTITUTED PYRAZOLO(3,4-d)PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
12/22/2004	EP1003476B1 Prolonged release active agent dosage form adapted for gastric retention
12/22/2004	EP0817648B1 Vascular endothelial cell growth factor antagonists
12/22/2004	EP0799045B2 Treatment of hyperexcited nerve cell functions
12/22/2004	EP0768889B1 Cancer therapy using lymphotoxin
12/22/2004	CN1556807A Chemical compounds
12/22/2004	CN1556716A Modular infusion device and method
12/22/2004	CN1556709A Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
12/22/2004	CN1556708A Methods for inhibiting cognitive deterioration in adults with down's syndrome
12/22/2004	CN1556705A 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives
12/22/2004	CN1556700A Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
12/22/2004	CN1556694A Method for obtaining aqueous formulations of oxidation-sensitive active principles
12/22/2004	CN1555889A Cellar air health care therapeutic agent
12/22/2004	CN1555888A Medicinal tablet or capsule for treating digestive ulcer
12/22/2004	CN1555887A Mineral composition and its manufacturing method
12/22/2004	CN1181048C Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha
12/21/2004	US6834238 Method for identifying optical contrast enhancing agents
12/21/2004	US6833378 Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders.
12/21/2004	US6833377 Composition and method for potentiating drugs
12/21/2004	US6833376 5-aminoalkyl and 5-aminocarbonyl substituted indole derivative useful for treatment of psychosis in a mammal
12/21/2004	US6833373 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
12/21/2004	US6833365 Such as 5-propionyl-6-cyclopentylsulfanylmethyl doxycycline; for treating diarrhea in immunodeficient individuals
12/21/2004	US6833364 Inhibiting degradation of cyclic guanosine monophosphate; cardiovascular disorders; such as 3-(4-amino-5-cyclopropyl-pyrimidin-2-yl)-1-(2-fluorobenzyl)1H-pyrazolo-(3,4 -b)-pyridine
12/21/2004	US6833360 Reacting pseudoephedrine with tannins at a temperature of about 50 to about 115 degrees C.; sustained release nasal decongestant
12/21/2004	US6833353 Inhibiting matrix metalloprotease (MMP) production using such as tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxy-ascomycin
12/21/2004	US6833349 Therapy for skin disorders; psoriasis
12/21/2004	US6833269 Stem cell culture product
12/21/2004	US6833243 For diagnosis of psychosis/schizophrenia via detection of mutant allele
12/21/2004	US6833141 Method of treating pruritis and composition thereof
12/21/2004	US6833140 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
12/21/2004	CA2227241C Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
12/16/2004	WO2004109390A1 Laser projector
12/16/2004	WO2004108747A2 Lectin conjugates
12/16/2004	WO2004108167A1 Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects
12/16/2004	WO2004108161A1 Solid pharmaceutical preparation
12/16/2004	WO2004108160A1 Osteogenesis-promotion enhancer and method of screening the same
12/16/2004	WO2004108153A1 Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds
12/16/2004	WO2004108138A1 Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea
12/16/2004	WO2004108137A1 A method of treating an anxiety disorder
12/16/2004	WO2004108130A1 Methods and compounds for the treatment of vascular stenosis
12/16/2004	WO2004108127A1 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
12/16/2004	WO2004108122A1 Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars)
12/16/2004	WO2004108120A1 Use of growth hormone secretagogues for treatment of fibromyalgia
12/16/2004	WO2004108119A2 Use of atp or derivatives in medicine
12/16/2004	WO2004108106A1 D-itch & equitch ointment & lotion for animal use
12/16/2004	WO2004108083A2 Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis
12/16/2004	WO2004108072A2 Delivery of immune response modifier compounds using metal-containing particulate support materials
12/16/2004	WO2004108062A2 Prophylaxis and/or treatment of portal hypertension
12/16/2004	WO2004107881A1 Nutritional compositions and use thereof
12/16/2004	WO2004096224A3 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
12/16/2004	WO2004089414A3 Combinations of proton pump inhibitors or blockers with prokinetic agents
12/16/2004	WO2004089353A3 Methods for treatment of parkinson's disease
12/16/2004	WO2004087212A3 Nitric oxide in treatment of inflammation
12/16/2004	WO2004087211A3 Inhibitors of phosphodiesterases in infertility
12/16/2004	WO2004087116A3 Drug combination for motor dysfunction in parkinson's disease
12/16/2004	WO2004075901A3 Compositon for increasing levels of hormones and a method for preparation of said composition
12/16/2004	WO2004064832A3 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
12/16/2004	WO2004047737A3 Nucleotide based medicament and method of use for treatment of conditions in humans

1 ... 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 ... 1151